After receiving this validation, we developed panels of guide RNAs for generating targeted mutations in the p53 tumour-suppressor gene. More than half of all cancers have mutations in p53 that ...

Another key discovery was a previously unnoticed p53 mutation (A276P) found in a subset of hTERT-RPE1 cells. This mutation weakened p53’s ability to regulate certain genes but did not affect its ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas.

Mutations in the TP53 gene occur in approximately half of human cancer types, with the TP53 Y220C mutation found in 1% of all solid tumors. Researchers from PMV Pharmaceuticals Inc. and collaborators ...

A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

Another key discovery was a previously unnoticed p53 mutation (A276P) found in a subset of hTERT-RPE1 cells. This mutation weakened p53's ability to regulate certain genes but did not affect its ...

14 In the excitement of discovery that sparked new explanations for cancer, scientists had quickly fit a label onto p53, but an oversight soon came to light. All the various tp53 and Trp53 clones used ...

No one really understands why activation of the tumor suppressor p53 sometimes leads to cell-cycle arrest and sometimes induces an apoptotic program. It has been proposed that post-translational ...

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP – Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $5.00 target ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.